Method for endothelioprotection in adma-similar gestosis model by arginase ii inhibitor

FIELD: pharmacology.

SUBSTANCE: method involves reproduction of gestosis in laboratory pregnant Wistar rats by daily intraperitoneal administration of the NO-synthase inhibitor L-NAME from day 14 to day 20 of pregnancy at a dose of 25 mg/kg/day. At that, correction of endothelial dysfunction is performed daily by intragastric administration of a selective inhibitor of arginase II-KUD975. Inhibitor administration is performed 30 minutes prior to the administration of L-NAME at a dose of 1 mg/kg of animal body weight.

EFFECT: pronounced correction of dysfunction under the conditions of specific mechanisms of the pathological process in pregnant women, with elimination of side effects typical for low- and nonselective arginase inhibitors.

1 ex

 



 

Same patents:

FIELD: medicine.

SUBSTANCE: biocompatible implant (BI) made of magnetic material in a biocompatible matrix (BM) is placed loosely along a posterior surface of an injured spinal cord of an experimental animal (EA) The EA is immersed periodically into a constant magnetic field. Its magnetic vector is aligned with a craniocaudal direction of spinal tracts. The BM of the BI is animal or herbal gelatine, wherein ferromagnetic magnetite or ferromagnetic ferrite nanoparticles 18-42 wt % with a particle size of 2.0-38 nm and at a magnetic field intensity (N) of 5-10 mT are immobilised as a magnetic material of the BI. The magnetic exposure covering the traumatic spinal injuries involves the combined effect of the magnetic field of the BI and the external rotating magnetic field at a magnetic induction of 0.15-0.35 T. The external magnetic exposure frequency is 1 or 2 times a day; the length is from 2 to 8 minutes per one session; the number of sessions is from 2 to 4. Animal gelatine in the BM of the BI can represent agar-agar, whereas herbal gelatine is pectin. The BM of the BI can additionally contain polyamines contributing to cell growth and proliferation, e.g. spermine or spemidine, in an amount of 1-5 wt %.

EFFECT: method enables recovering the spinal cord function sufficiently completely in the distal direction from the injury region, providing the favourable conditions for the adequate neuroglial growth with recipient's long neuron penetration from the intact proximal portion of the spinal cord into the distal one to ensure its conductive function, reducing the cicatrisation within the spinal injury, and eliminating the cerebral tissue oedema.

3 cl, 8 ex

FIELD: medicine.

SUBSTANCE: to a laboratory animal - rat - carried out is a unilateral nephrectomy, denervation and delymphatisation of the second kidney. After that the renal artery and vein are clamped for 40-60 minutes. After carrying out the surgical operation the triple immunisation of the laboratory animal with a kidney antigen, obtained from the removed kidney is carried out by an adjuvant method. 5 weeks before the surgical operation sampling of bone marrow cells from the laboratory animal is carried out, a culture of multipotent mesenchymal stromal cells is obtained from them in vitro. The denervation and delymphatisation of the remaining kidney is carried out by the removal of the adventitia and cellular tissue, wrapping the ureter, renal artery and vein, in the area of the hiluses renalis at a distance of 7-10 mm and decapsulation of the kidney in the area of its medial edge 7-10 mm wide, extension from one pole of the kidney to the other with the capture of the area of its hiluses. To obtain the kidney antigen the safe kidney is applied and the content of protein in it is brought to 70 mg/ml. On 35-40 day after carrying out the surgical operation the obtained culture of the multipotent mesenchymal stromal cells is introduced to the same animal intravenously in a dose of 1.5-3.0 mln cells in 1 ml of physiological solution.

EFFECT: method makes it possible to create an adequate, available for execution model of chronic rejection in autologous kidneys in small laboratory animals with an accelerated development of visualised destructive post-transplantation processes.

1 ex, 1 tbl, 9 dwg

FIELD: medicine.

SUBSTANCE: chemical burn is simulated in laboratory rats. From the 5th day following the simulation, therapeutic agents are administered abdominally. That involves using cefotaxime 100 mg/kg for 7 days. Prednisolone is administered in a dose of 1 mg/kg for 3 days. 3% Xymedone is administered in a dose of 30 mg/kg once a day for 40 days.

EFFECT: effective treatment of burns of the oesophagus and stomach by fast recovery of the thickness of a muscular layer of the mucous tunic and prevention of cicatrisation.

1 tbl, 16 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medical equipment tests, namely to production tests of joint implants with a metal friction pair the state of which is assessed in the course of testing with using electric (electrically resistive) diagnostic techniques. The diagnostic technique for joint implants with the metal friction pair consisting in the fact that the implant is mounted in a test bench loaded with axial force; a lubricant layer is formed between surfaces of the implant components, and the physical characteristics of the surface layer of the components in the friction zone are measured. Small AC current is passed through the friction zone of the implant; a temporary function of complex impedance of the implant tribocoupling is recorded; it uses its active and reactive component parameters to show an actual thickness of the lubricant layer and a lubricant type prevailing in the tribocoupling and a friction regimen. The actual technical condition of the joint implant tribocoupling is assessed by a ratio of the time intervals when the active part of the complex impedance is more than the reactive part to the total measurement time.

EFFECT: invention provides shortening the test time, assessing the real time of the contact of the friction surfaces, increasing the produced valid signal power and noise stability, in obtaining the objective initial diagnostic information from the friction zone in order to predict a durability of the joint implant with the metal friction pair.

5 dwg

FIELD: medicine.

SUBSTANCE: stimulating the excised liver regeneration is ensured by a 70% hepatectomy into a laboratory animal on the second day of the experiment. A liver regeneration stimulator is presented by L-norvaline administered intragastrically in a daily dose of 10.0 mg/kg every 46 hours for the first 7 days of the experiment.

EFFECT: method provides the effective stimulation of the excised liver regeneration evidenced by reducing the animals' lethality, improved hepatic microcirculation, reduced manifestation of cytolysis and enhanced synthetic function of the liver.

2 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: limb ischemia is simulated in a male Wistar rat anaesthetised with chloral hydrate in a dose of 250-300 mg/kg by the surgical removal of femoral, popliteal arteries and the front shin artery. That is followed by introducing a prepared mononuclear fraction of the autologous bone marrow in a dose of 4×106 cells in an amount of 200 mcl. The above is introduced into the ischemic limb from two points in an amount of 100 mcl each. One point is found directly under the femoral arch paravasally within the anatomical position of collaterals of the inner iliac artery and its branches. The other point is located in the calf muscle on an anteriolateral surface of the midleg.

EFFECT: more effective experimental treatment ensured by stimulating the collateral blood flow in the ischemic limb and improving the arterial blood flow from the proximal to distal parts of the limb.

1 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: method consists in a single administration of a mixture consisting of a rat's homogenised myocardial tissue - 25%, egg albumin - 25% and Freund's adjuvant - 50%, into old male rats. The method involves administering in an amount of 0.3 ml into 5 injection points: intraperitoneally, into inguinal and axillary regions from the left and right.

EFFECT: being easy to reproduce and cost efficient, the method is effective for creating a model aiming at a possibility of studying the pathogenesis, preventing and treating cardiopathy.

2 dwg, 1 tbl, 1 ex

Phantom test // 2555129

FIELD: medicine.

SUBSTANCE: phantom test consists of two parts being a single whole. One part has a constant longitudinal height, while the other part has a continuously varying longitudinal height forming a wedge. On the side of the wedge, there are calibrated notches.

EFFECT: more accurate determination of the bone mineral density by X-ray images formed with the help of a general-application X-ray machine, and simplifying the design.

7 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to gastroenterology, pathologic physiology, and concerns simulating acute pancreatitis. To this effect, the method involves ligaturing the main truck of the excretory duct of the pancreas, administering an aggressive solution into the pancreatic duct system, and removing the ligature. The aggressive solution represents 1% chenodeoxycholic acid with 5% sodium hydrogen carbonate in an equal proportion in an amount of 0.3-0.5 ml at 10-15 mg/kg of the animal's body weight.

EFFECT: method enables developing a model of acute fatty, hemorrhagic or mixed pancreatitis in the animal that makes it applicable for improving the known methods for conservative and radical methods of treating.

15 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to ophthalmology, and concerns simulation in vivo of cortical cataract. That is ensured by a double-side surgical sympathectomy by excising a superior cervical sympathetic ganglion.

EFFECT: by simplicity and effectiveness of modulation, the method provides forming the cortical lens-form opacity, which is morphologically and immunohistochemically identical to lens cell changes in age-related lens opacity in a human.

6 dwg, 2 tbl

FIELD: medicine.

SUBSTANCE: presented group of inventions refers to medicine. What is presented is a method of treating visceral pain and/or one or more symptoms of visceral pain, involving administering a therapeutically effective amount of an antagonist antibody against calcitonin gene-related peptide (CGRP) into an individual suffering visceral pain, or an individual suffering a risk of visceral pain, wherein the CGRP agonist antibody is applicable for peripheral administration. What is also presented is a pharmaceutical composition containing the CGRP agonist antibody and a pharmaceutically acceptable carrier, applicable for peripheral administration.

EFFECT: presented group of inventions provides the effective treatment of visceral pain with using no opiates.

18 cl, 3 dwg, 2 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: present group of inventions refers to medicine, namely to neurology and cardiology, and concerns treating a complication related to an aneurysmal subarachnoidal haemorrhage. That is ensured by determining the patient's plasma citrulline, and if observing a decrease thereof, an effective amount thereof is administered.

EFFECT: method provides effective treatment of such complication as the vasospasm by increasing the nitrogen oxide level.

16 cl, 1 dwg, 2 ex

FIELD: medicine.

SUBSTANCE: invention represents a coronarodilating medication in the form of a tablet, which contains a solution of levomenthol in menthyl isovalerate (validol), isomalt, and calcium or magnesium stearate.

EFFECT: obtaining the coronarolitating medication by a method of direct pressing, which does not contain sugar, is characterised by dosage homogeneity, storage stability, high bioavailability.

2 cl, 11 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: method involves simulating endothelial dysfunction in Wistar male rats by daily intraperitoneal introduction of L-nitro-arginine-methyl ester 25 mg/kg/day for 7 days. Endothelial dysfunction is corrected by intragastric introduction of an api-phytocomposition in the form of an aqueous suspension of honey, royal jelly, bee bread, Resveratrol in the ratio of 10:1:1:2. The composition is introduced in a dose of 200 mg/kg of an animal's body weight once a day for 7 days.

EFFECT: method provides synergetic endothelioprotective effects with no side effects observed when treating with synthetic preparations.

1 ex

FIELD: medicine.

SUBSTANCE: method involves simulating gestosis in Wistar rats by the daily intraperitoneal introduction of L-nitro-arginine-methyl ester 25 mg/kg for 7 days. That is followed by the intragastric introduction of azithromycin 30 mg/kg once a day in the setting of the model above from 14th to 20th day of pregnancy.

EFFECT: method provides the manifested endothelial dysfunction correction in the special pathogenesis environment in the pregnant females in a combination with eliminating acute infectious diseases or aggravated chronic infectious processes that can also lead to the formation of gestosis.

1 ex

FIELD: medicine.

SUBSTANCE: nitrogen oxide deficiency is simulated by the daily 7-day intraperitoneal introduction of N-nitro-L-arginine methyl ester 25 mg/kg into experimental Wistar male rats. The nitrogen oxide deficiency is corrected by the simultaneous 7-day intragastric introduction of a combination of tadalafil 0.09 mg/kg and L-norvaline 10 mg/kg once a day.

EFFECT: effective management of the nitrogen oxide deficiency stimulated as described above by the therapeutic combination of the preparations first identified to this effect.

1 ex, 2 tbl

FIELD: medicine.

SUBSTANCE: endothelial dysfunction is induced in experimental Wistar male rats for 28 days by daily intraperitoneal introduction of N-nitro-L-arginine methyl ester (L-NAME) 12.5 mg/kg a day. An agent for dysfunction correction is a mixture of solutions of homoeopathic dilutions of angiotensin II receptor C-terminal fragment antibodies - C12, C30, C200. This mixture is introduced at the same time for 28 day intragastrically 2 times a day in a dose of 4.5 ml/kg.

EFFECT: method provides effective endothelial dysfunction correction with eNOS increase.

1 tbl

FIELD: medicine.

SUBSTANCE: claimed group of inventions relates to medicine, namely to angiology, and deals with treatment of diseases of peripheral vessels. For this purpose pharmaceutical composition, containing efficient amount of 11-deoxy-prostaglandin compound, characterised by general formula III, is introduced.

EFFECT: introduction of said composition ensures enhancement of peripheral blood flow, reduction of intraocular pressure, recovery of barrier function and increase of ATP level in endothelial cells with absence of impact on arterial pressure and heart rate.

17 cl, 8 ex, 5 tbl, 22 dwg

FIELD: medicine.

SUBSTANCE: endothelial dysfunction is experimentally simulated in male white Wistar rats by daily intraperitoneal introduction of the endothelial synthetase inhibitor L-nitro-L-arginine-methyl ester 25 mg/kg for 7 days A degree of dysfunction development is estimated by the relation of endothelium-dependent and endothelial-independent vasodilation. Endothelial dysfunction is corrected by daily inhalations of mixed helium and oxygen in the amount of 150 ml and 50 ml respectively, for 7 days.

EFFECT: method provides evident endothelial dysfunction correction.

1 ex, 2 tbl

FIELD: medicine.

SUBSTANCE: endothelial dysfunction is induced in experimental Wistar male rats for 28 days by daily intraperitoneal introduction of N-nitro-L-arginine methyl ester (L-NAME) 12.5 mg/kg a day. An agent for dysfunction correction is a mixture of solutions of homoeopathic dilutions of tumour necrosis factor-alpha (TNF-α) antibodies - C12, C30, C200. This mixture is introduced at the same time for 28 day intragastrically 2 times a day in a dose of 4.5 ml/kg.

EFFECT: effective endothelial dysfunction correction.

1 tbl

FIELD: medicine.

SUBSTANCE: standard therapy of acute pancreatitis with spasmolytic, antibacterial, antisecretory and histoprotective preparations in pregnant women is accompanied with prescribing natural micronised progesteron additionally from the first days in a dose of 200mg intravaginally, daily for the night till the gestational age of 37 weeks + 1 day. Besides, two sessions of discrete plasmapheresis on the first and third therapeutic day.

EFFECT: method enables the reliable prevention of obstetric complications and premature delivery in developing acute pancreatitis.

2 ex, 3 tbl

Up!